Home
>
US Stocks
>
Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd
BHVN

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

$115.950.79%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$116.57
Today Low/High$115.34 / $118.56
52 Week Low/High$62.57 / $151.51
P/E ratio-8.47
Market Cap$7.54B

Company Details

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
OrganisationBiohaven Pharmaceutical Holding Company Ltd
HeadquatersNew Haven, Connecticut, US
Employees825
IndustryHealth Technology
CEOVlad Coric

Discover more

Frequently Asked Questions

What is Biohaven Pharmaceutical Holding Company Ltd (BHVN) share price today?

Can Indians buy Biohaven Pharmaceutical Holding Company Ltd (BHVN) shares?

How can I buy Biohaven Pharmaceutical Holding Company Ltd (BHVN) shares from India?

Can Fractional shares of Biohaven Pharmaceutical Holding Company Ltd (BHVN) be purchased?

What are the documents required to start investing in Biohaven Pharmaceutical Holding Company Ltd (BHVN) stocks?